hydralazine has been researched along with 9,10-dimethyl-1,2-benzanthracene in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A | 1 |
1 other study(ies) available for hydralazine and 9,10-dimethyl-1,2-benzanthracene
| Article | Year |
|---|---|
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenovirus E1A Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Ethinyl Estradiol; Female; Galectin 3; Gene Expression; Gene Silencing; Histocompatibility Antigens Class I; Humans; Hydralazine; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mammary Neoplasms, Experimental; Neoplasm Recurrence, Local; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Trans-Activators; Valproic Acid | 2017 |